Background: The SELECT‐D trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared to dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. Objectives: To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months Patients/Methods: In SELECT‐D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomisation to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The secon...
© JNCCN-Journal of the National Comprehensive Cancer Network. Background: Although not designated as...
BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous th...
Background: Although many patients with venous thromboembolism require extended treatment, it is unc...
Background The SELECT‐D trial demonstrated reduction in recurrent venous thromboembolism (VTE) but i...
BACKGROUND The SELECT-D trial demonstrated reduction in recurrent venous thromboembolism (VTE) bu...
BACKGROUND The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venou...
INTRODUCTION: Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical ...
Purpose: Venous thromboembolism (VTE) is common in cancer patients. Long-term daily subcutaneous...
© 2018 by American Society of Clinical Oncology. Purpose Venous thromboembolism (VTE) is common in p...
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous...
ntroduction Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical pr...
Purpose: Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneo...
Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment...
In cancer patients treated for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) an...
In cancer patients treated for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) an...
© JNCCN-Journal of the National Comprehensive Cancer Network. Background: Although not designated as...
BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous th...
Background: Although many patients with venous thromboembolism require extended treatment, it is unc...
Background The SELECT‐D trial demonstrated reduction in recurrent venous thromboembolism (VTE) but i...
BACKGROUND The SELECT-D trial demonstrated reduction in recurrent venous thromboembolism (VTE) bu...
BACKGROUND The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venou...
INTRODUCTION: Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical ...
Purpose: Venous thromboembolism (VTE) is common in cancer patients. Long-term daily subcutaneous...
© 2018 by American Society of Clinical Oncology. Purpose Venous thromboembolism (VTE) is common in p...
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous...
ntroduction Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical pr...
Purpose: Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneo...
Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment...
In cancer patients treated for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) an...
In cancer patients treated for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) an...
© JNCCN-Journal of the National Comprehensive Cancer Network. Background: Although not designated as...
BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous th...
Background: Although many patients with venous thromboembolism require extended treatment, it is unc...